IDEXX Laboratories Inc

IDXX has broken a key horizontal support zone with expanding down-day volume, and price sits below the 9, 20, 50, and 200 moving averages. The active Support Failure pattern signals buyers can no longer absorb supply, implying further downside. With EMAs sloping lower and RSI deeply oversold but lacking divergence, short-term conditions favor immediate sell-side participation rather than waiting for any relief bounce.

• ↑Q2 revenue of $1.217B (+10% YoY) and EPS $4.27 (+18%), prompting raised full-year guidance
• ↑Operating margin at 35% (+140 bp) and free cash flow $323M in Q2, targeting 90–100% conversion
• ↓U.S. same-store clinical visits fell 1.3%, limiting revenue growth